Moneycontrol PRO

business

Sun Pharma maintains 13-15% FY15 topline guidance: CFO

The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.

first published: Feb 18, 2015 02:54 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347